These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32854099)

  • 1. One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey.
    Bejinariu AG; Makimoto H; Wakili R; Mathew S; Kosiuk J; Linz D; Steinfurt J; Dechering DG; Meyer C; Veltmann C; Kelm M; Frommeyer G; Eckardt L; Deneke T; Duncker D; Müller P
    Cardiology; 2020; 145(10):676-681. PubMed ID: 32854099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of periprocedural anticoagulation strategy on the incidence of new-onset silent cerebral events after radiofrequency catheter ablation of atrial fibrillation.
    Müller P; Halbfass P; Szöllösi A; Dietrich JW; Fochler F; Nentwich K; Roos M; Krug J; Schmitt R; Mügge A; Deneke T
    J Interv Card Electrophysiol; 2016 Sep; 46(3):203-11. PubMed ID: 27020439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation.
    Mao YJ; Wang H; Huang PF
    J Interv Card Electrophysiol; 2021 Apr; 60(3):407-417. PubMed ID: 32361948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study.
    Tang L; Liu H; Deng H; Zhan X; Fang X; Liao H; Liu Y; Fu L; Fu Z; Liu H; Wu S; Xue Y
    Front Med (Lausanne); 2020; 7():197. PubMed ID: 32582721
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).
    Potpara TS; Larsen TB; Deharo JC; Rossvoll O; Dagres N; Todd D; Pison L; Proclemer A; Purefellner H; Blomström-Lundqvist C;
    Europace; 2015 Jun; 17(6):986-93. PubMed ID: 26023177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
    Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
    BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation.
    Black-Maier E; Kim S; Steinberg BA; Fonarow GC; Freeman JV; Kowey PR; Ansell J; Gersh BJ; Mahaffey KW; Naccarelli G; Hylek EM; Go AS; Peterson ED; Piccini JP;
    Clin Cardiol; 2017 Sep; 40(9):746-751. PubMed ID: 28543401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nationwide survey of catheter ablation for atrial fibrillation: The Japanese catheter ablation registry of atrial fibrillation (J-CARAF)-A report on periprocedural oral anticoagulants.
    Murakawa Y; Nogami A; Shoda M; Inoue K; Naito S; Kumagai K; Miyauchi Y; Yamane T; Morita N; Mitamura H; Okumura K;
    J Arrhythm; 2015 Feb; 31(1):29-32. PubMed ID: 26336520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.
    Hohnloser SH; Camm AJ; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Lanz HJ; Rauer H; Reimitz PE; Smolnik R; Kautzner J
    Europace; 2021 Jan; 23(1):65-72. PubMed ID: 33249467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catheter ablation of atrial flutter: A survey focusing on post ablation oral anticoagulation management and ECG monitoring.
    Attanasio P; Budde T; Lacour P; Parwani AS; Pieske B; Blaschke F; Haverkamp W; Boldt LH; Huemer M
    Pacing Clin Electrophysiol; 2017 Jul; 40(7):788-793. PubMed ID: 28548234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.
    Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA
    Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Periprocedural Management of Novel Oral Anticoagulants During Atrial Fibrillation Ablation: Controversies and Review of the Current Evidence.
    Abed HS; Chen V; Kilborn MJ; Sy RW
    Heart Lung Circ; 2016 Dec; 25(12):1164-1176. PubMed ID: 27425183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
    Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
    BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
    Hohnloser SH; Basic E; Nabauer M
    Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periprocedural Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation Without Discontinuation of a Vitamin K Antagonist and Direct Oral Anticoagulants.
    Kojima T; Fujiu K; Fukuma N; Matsunaga H; Oshima T; Matsuda J; Matsubara T; Shimizu Y; Oguri G; Hasumi E; Morita H; Komuro I
    Circ J; 2018 May; 82(6):1552-1557. PubMed ID: 29657252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation.
    van Vugt SPG; Westra SW; Volleberg RHJA; Hannink G; Nakamura R; de Asmundis C; Chierchia GB; Navarese EP; Brouwer MA
    Europace; 2021 Dec; 23(12):1961-1969. PubMed ID: 34333631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation.
    Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H
    Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation.
    Hansen PS; Sanchez R; Walfridsson H
    Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
    Martinez C; Katholing A; Wallenhorst C; Freedman SB
    Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral thromboembolic risk in atrial fibrillation ablation: a direct comparison of vitamin K antagonists versus non-vitamin K-dependent oral anticoagulants.
    Petzl A; Derndorfer M; Kollias G; Moroka K; Aichinger J; Pürerfellner H; Martinek M
    J Interv Card Electrophysiol; 2021 Jan; 60(1):147-154. PubMed ID: 32144677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.